A new anti-rape drug is being developed by scientists and the US military, but there is some concern about its safety and impact on men.
A group of US scientists is working to develop the drug to fight sexual assault and other crimes against women.
The new drug is named “Anti-Rape Device” (ARD).
Its design is based on “a device designed to reduce the pain of sexual assault”, which would then cause “increased sexual activity”, according to the company that makes it.
It is expected to be available by 2020.
The drug has been approved by the US Food and Drug Administration (FDA) for the treatment of sexual harassment, sexual assault, stalking and rape.
The company behind it, BioToxie Pharmaceuticals, said it had been funded by the Defense Department’s Office of Science and Technology to develop and commercialise its technology.
The team of researchers are led by Dr Jody Zuckerman, the chief medical officer of the company.
The scientists behind ARD are looking at a range of applications, including preventing rape and sexual assault of pregnant women.
Dr Zuckermere said the drug could be used to “provide immediate and effective relief to victims of sexual violence and to prevent future victimization”.
“This device may also be useful for the prevention of domestic violence and other forms of physical and psychological abuse,” Dr Zugerman said.
“The objective is to provide immediate relief to the victims of these crimes, while also providing a safe environment for future victims.”
Dr Zinkerman said he was excited about the potential of the drug.
“This drug could potentially be the first of its kind to address the problem of sexual abuse,” he said.
The study was published in the journal Drug Safety and was funded by an anonymous donor.
The FDA said that it would work with BioToxin to evaluate the safety and effectiveness of the product and to ensure that it meets all safety standards.
“We look forward to the potential clinical trials that could be undertaken to determine whether ARD is safe and effective for use by women, and whether it can provide immediate and lasting relief to sexual assault victims,” Dr Paul Hochberg, chief of the FDA’s Center for Drug Evaluation and Research, said in a statement.
A number of studies have found that the drug has limited efficacy for women, though Dr Zooker said the research showed that the product would work in men.
Dr Hochbi said that ARD’s “safety profile will be further evaluated during Phase 2 clinical trials”.
“It will be important to continue to monitor safety and efficacy in this Phase 2 study and for subsequent Phase 2 trials to determine if the ARD has any efficacy for this population,” he added.
ARD was initially developed as a therapeutic for sexual assault but is being marketed as a safer alternative to existing treatment options.
“For some of these patients, the potential benefits are greater than those of existing treatments,” Dr Hachberg said.
He added that the “potential safety and long-term efficacy of ARD will be evaluated in the larger population of women with sexual assault.”
The study of ARDS was conducted by the National Institutes of Health (NIH) under the leadership of Dr Hichberg.
It involved an initial phase of clinical trials, followed by a two-year follow-up.
“To our knowledge, this is the first time the FDA has approved the use of an ARD in a human trial,” said Dr Hachiwari Gaudreault, an assistant professor of psychology at the University of California, San Diego.
“With the approval of this product, we have shown that the safety profile of this drug is comparable to existing treatments, which are generally very effective,” she said.
In the first phase of the study, which was funded and supervised by the NIH, participants were randomly assigned to take one of two doses of the ARDS: a placebo or ARD.
The trial lasted a total of six months.
The researchers also tested the drug on three types of sexual assaults: non-consensual sex, non-violent sexual assault or rape, and forced sexual intercourse.
The women were randomly divided into three groups.
The first group received the drug for 12 weeks.
The second group took it for six weeks.
In between, participants who took the drug had to report how many sexual assaults they had experienced in the previous month.
The third group took the medication for 12 months.
Researchers also took blood samples from the participants after 12 months, and were able to compare the blood to the baseline samples.
In a second phase of research, researchers also administered the drug directly to the participants.
In this study, participants received the drugs for a total duration of three weeks.
Participants in the first and second phase also had to give urine samples at the end of the six-month study to be monitored for the presence of the drugs.
Dr Gaudret said that, in the initial phase, the participants were given an average of